Daesung Microbiological Labs. Co., Ltd.

KOSDAQ:A036480 Stock Report

Market Cap: ₩35.2b

Daesung Microbiological Labs Past Earnings Performance

Past criteria checks 0/6

Daesung Microbiological Labs's earnings have been declining at an average annual rate of -55.1%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 0.08% per year.

Key information

-55.1%

Earnings growth rate

-54.9%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate0.08%
Return on equity-8.2%
Net Margin-11.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

Feb 17
We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 19
Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Recent updates

Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of Debt

Aug 06
Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of Debt

Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?

May 08
Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?

Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

Mar 15
Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?

We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

Feb 17
We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability

Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?

Jan 21
Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?

Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five Years

Dec 31
Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five Years

Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?

Dec 10
Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?

Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 19
Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential

Revenue & Expenses Breakdown

How Daesung Microbiological Labs makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A036480 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2424,164-2,7994,7570
30 Jun 2424,009-2,6024,6890
31 Mar 2425,423-1,1474,9510
31 Dec 2325,562-6804,8160
30 Sep 2325,502-6744,6790
30 Jun 2324,7964414,6220
31 Mar 2324,8711274,3040
31 Dec 2225,5001,7034,3840
30 Sep 2225,1672,4934,5210
30 Jun 2225,6492,1744,6620
31 Mar 2224,7602,5684,6760
31 Dec 2123,9978664,7060
30 Sep 2123,179-2655,2210
30 Jun 2123,3743355,3500
31 Mar 2123,6167665,2370
31 Dec 2024,8011,5195,4730
30 Sep 2025,4082,0584,7470
30 Jun 2024,5151,8824,4360
31 Mar 2025,8682,5104,6840
31 Dec 1925,1342,4714,2960
30 Sep 1924,9183,5664,2950
30 Jun 1926,5444,2554,3360
31 Mar 1925,4833,6224,2380
31 Dec 1825,0973,1704,1850
30 Sep 1824,1592,0984,1930
30 Jun 1824,0881,6544,3380
31 Mar 1824,1511,6864,4210
31 Dec 1724,0431,5584,6500
30 Sep 1726,0222,6114,9330
30 Jun 1727,3533,0894,8760
31 Mar 1728,5493,4754,7760
31 Dec 1630,8014,4954,6820
30 Sep 1631,8054,5834,4650
30 Jun 1629,8684,1674,4550
31 Mar 1631,0864,2134,4510
31 Dec 1531,0264,5504,3800
30 Sep 1529,4293,7864,3880
30 Jun 1530,6043,8354,2770
31 Mar 1527,9023,2934,2090
31 Dec 1425,2982,0424,1470
30 Sep 1424,7091,1053,9140
30 Jun 1423,7478304,0120
31 Mar 1422,5586244,1620
31 Dec 1321,6334333,9430

Quality Earnings: A036480 is currently unprofitable.

Growing Profit Margin: A036480 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: A036480 is unprofitable, and losses have increased over the past 5 years at a rate of 55.1% per year.

Accelerating Growth: Unable to compare A036480's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A036480 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).


Return on Equity

High ROE: A036480 has a negative Return on Equity (-8.16%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 13:36
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Daesung Microbiological Labs. Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution